# Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab

> **NCT01328366** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 153 (actual)

## Conditions studied

- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01328366
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2015-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328366, "Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01328366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*